Valuation: Poxel

Market Cap 12.57M 14.56M 11.83M 10.75M 20.22M 1.39B 20.52M 139M 54.38M 698M 54.65M 53.47M 2.32B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 92.23M 74.94M 68.11M 128M 8.84B 130M 879M 345M 4.42B 346M 339M 14.72B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day+1.34%
1 week-1.10%
Current month-5.87%
1 month-1.00%
3 months-20.64%
6 months-27.90%
Current year-15.73%
1 week 0.19
Extreme 0.1926
0.2
1 month 0.19
Extreme 0.1926
0.22
Current year 0.19
Extreme 0.1926
0.48
1 year 0.19
Extreme 0.1926
0.48
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 09/06/2026
Director of Finance/CFO - 30/11/2022
Corporate Officer/Principal - 30/04/2023
Director TitleAgeSince
Chairman - 30/07/2025
Director/Board Member - 30/07/2025
Director/Board Member - 30/07/2025
Date Insider Type Main position Quantity % Market Cap.
04/02/22 Fiscal year

Founder

67,000 0.2334%
04/02/22 Fiscal year

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
+1.34%-1.10%-43.01%-66.52% 12.11M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.51%+14.93%+56.46%+91.76% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
+1.05%+4.57%+40.55%-14.63% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average +1.61%+2.54%+47.00%+171.26% 28.05B
Weighted average by Cap. +1.35%+5.48%+57.16%+164.28%

Financials

2023 2024
Net sales 1.98M 2.29M 1.86M 1.69M 3.19M 220M 3.23M 21.86M 8.57M 110M 8.61M 8.42M 366M 6.64M 7.68M 6.24M 5.67M 10.67M 736M 10.83M 73.24M 28.7M 368M 28.85M 28.22M 1.23B
Net income -35.09M -40.63M -33.02M -30.01M -56.44M -3.89B -57.26M -387M -152M -1.95B -153M -149M -6.48B -18.3M -21.19M -17.22M -15.65M -29.44M -2.03B -29.87M -202M -79.17M -1.02B -79.57M -77.84M -3.38B
Net Debt 46.42M 53.75M 43.68M 39.7M 74.66M 5.15B 75.76M 512M 201M 2.58B 202M 197M 8.58B 67.08M 77.67M 63.12M 57.36M 108M 7.44B 109M 740M 290M 3.72B 292M 285M 12.4B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
19/08/26 0.1972 +1.34% 68,721
18/08/26 €0.1946 -1.72% 402,963
17/08/26 €0.1980 -2.22% 563,583
14/08/26 €0.2025 +0.50% 498,658
13/08/26 €0.2015 +1.05% 145,851
  1. Stock Market
  2. Stocks
  3. POXEL Stock